Psilocybin FDA Approval Status (Updated May 2026) — Tracker & Timeline

Psilocybin is closer to FDA approval than ever before. COMPASS Pathways achieved two consecutive positive Phase 3 trials for its COMP360 psilocybin therapy in treatment-resistant depression, hitting primary endpoints with high statistical significance in both COMP005 (June 2025) and COMP006 (February 2026). The company has a rolling NDA submission underway, with practical completion gated on early Q3 2026 Part B data, and a potential FDA approval decision by late 2026 or early 2027 — which would make COMP360 the first classic psychedelic ever approved by the U.S. Food and Drug Administration.

Meanwhile, the state-level landscape has transformed: Oregon's psilocybin service centers have served roughly 16,000 clients since launch, Colorado now has 34 licensed healing centers, and New Mexico became the first state to legalize medical psilocybin through legislation in April 2025. This tracker covers every major development in the psilocybin FDA approval timeline, state legalization status, clinical pipeline, and regulatory landscape. Updated May 25, 2026.

---

Latest Updates

• May 13, 2026 — Compass Pathways Q1 2026 earnings call confirms rolling NDA submission is underway, with completion gated on early Q3 Part B COMP006 data. Cash position $466.0M, runway into 2028. Company "launch ready" by end of 2026. (Source: Business Wire press release, Motley Fool transcript)
• May 6, 2026 — Connecticut House passes SB 191 (122-27), expanding the state psychedelic-assisted therapy pilot program. Awaiting Gov. Lamont's signature. (Source: Connecticut General Assembly)
• April 24, 2026 — FDA issues three Commissioner's National Priority Vouchers to psychedelic programs: Compass Pathways (COMP360 psilocybin for TRD), Usona Institute (psilocybin for MDD), and Transcend Therapeutics (methylone for PTSD). FDA also grants Compass rolling NDA submission and review. (FDA press release)
• April 22, 2026 — Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," published in Federal Register (91 FR 21709). (Federal Register)
• April 13, 2026 — Virginia Gov. Abigail Spanberger signs HB 1347 / SB 379, directing the Board of Pharmacy to reschedule FDA-approved psilocybin formulations consistent with federal scheduling.
• April 9, 2026 — Connecticut Senate votes 35-0 to expand state psychedelics pilot program. (Source: Marijuana Moment)
• March 24, 2026 — South Dakota Gov. Larry Rhoden signs HB 1099, reclassifying FDA-approved crystalline polymorph psilocybin to Schedule IV under state law upon FDA approval.

---

COMPASS Pathways' COMP360 Leads the Race to FDA Approval

COMPASS Pathways (Nasdaq: CMPS) holds the most advanced psilocybin program in the world. Its synthetic, pharmaceutical-grade psilocybin formulation, COMP360, received FDA Breakthrough Therapy Designation in 2018 for treatment-resistant depression (TRD) — a condition affecting roughly 2.8 million Americans who fail to respond to at least two conventional antidepressants.

The company has now achieved positive results across three clinical trials enrolling over 1,000 participants, going 3-for-3 on primary endpoints.

COMP005 (first Phase 3 trial) enrolled 258 patients across 32 U.S. sites in a randomized, double-blind, placebo-controlled design. Topline results disclosed in June 2025 showed a single 25 mg dose of COMP360 produced a mean treatment difference of -3.6 points on the MADRS depression scale versus placebo (95% CI: [-5.7, -1.5]; p < 0.001). Statistically significant improvement appeared the day after administration and was maintained through Week 6. Long-term durability data through 26 weeks showed that patients who achieved clinically meaningful improvement maintained their benefit, and over 40% of non-remitters went into remission after a second dose.

COMP006 (second Phase 3 trial) enrolled 581 patients across sites in North America and Europe in an active-controlled design comparing two fixed doses (given three weeks apart) at 25 mg, 10 mg, and 1 mg. Results disclosed on February 17, 2026 showed the 25 mg arm achieved a mean treatment difference of -3.8 MADRS points versus the 1 mg control (95% CI: [-5.8, -1.8]; p < 0.001). Notably, 39% of participants in the 25 mg group achieved clinically meaningful MADRS reduction at Week 6, and there were zero instances of suicidal ideation in the active-dose arm.

Safety across both trials was consistent: most treatment-emergent adverse events (headache, nausea, visual hallucination) occurred on dosing days, with 88% resolving within 24 hours. Serious adverse events were reported in roughly 2–5% of participants, and suicidal ideation SAEs occurred in less than 1% of the 25 mg groups.

---

The NDA Timeline and What Comes Next

Following the COMP006 results, Compass requested and FDA granted a rolling NDA submission — a process that allows sections of the application to be reviewed as they are submitted rather than waiting for the complete package. As confirmed on the May 13, 2026 Q1 earnings call, rolling submission is already underway, with modules being filed on an ongoing basis. The 26-week Part B durability data from COMP006 is the final dataset required to complete the submission. Per CEO Kabir Nath: "Part B data from 006, which we continue to expect in early Q3, will be the final data set to complete the submission."

The current projected timeline:

• Early Q3 2026: 26-week Part B durability data from COMP006
• Q3 2026: Rolling NDA submission completion
• Q4 2026 – Q1 2027: Potential FDA approval decision under CNPV program review (1-2 month review goal following final NDA submission)

Compass reiterated on the May 13 call that the company will be "launch ready by the end of this year" and reported its commercial team has doubled in the past two months. The launch leadership team has "collectively launched over 50 products," and operational preparations are advanced.

Independent experts have characterized the COMP360 data as sufficient for approval. Sandeep Nayak of the Johns Hopkins Center for Psychedelic & Consciousness Research told Psychedelic Alpha, "I anticipate this will get approved." Analysts at RBC Capital raised their price target to $22 with an Outperform rating, while GlobalData projects $879 million in COMP360 sales by 2031.

Important caveats remain. The CNPV 1-2 month review window is a program goal, not a binding statutory commitment — both FDA and Compass have been careful with the framing. No PDUFA date exists because the NDA is not yet complete. Even after approval, DEA must reschedule the specific approved formulation, a process that adds additional months in the conventional sequential model, though EO 14401 §5 contemplates parallel DEA review. H.C. Wainwright analyst Patrick Trucchio noted that a Q4 2027 commercial launch would be "optimistic" — that estimate predates the EO and CNPV developments, and the practical launch window has likely compressed.

COMPASS also expanded its clinical ambitions in January 2026 when the FDA accepted an IND application for COMP360 in PTSD, enabling a Phase 2b/3 trial. A Phase 2 open-label PTSD study had already shown a 29.5-point reduction in CAPS-5 scores at 12 weeks. The company raised approximately $341 million in February 2026 through a public offering and warrant exercises, extending its cash runway into 2028.

---

The Broader Psilocybin and Psychedelic Clinical Pipeline

COMP360 is not the only game in town. Multiple companies are advancing psilocybin and related psychedelic compounds through FDA trials, creating a pipeline that could deliver several approved psychedelic therapies within the next few years.

Usona Institute, a nonprofit, holds the second FDA Breakthrough Therapy Designation for psilocybin — granted in 2019 for major depressive disorder (MDD), a broader indication than COMPASS's TRD focus. Its Phase 3 trial (uAspire, NCT06308653) launched in March 2024, randomizing approximately 240 adults to 25 mg psilocybin, 5 mg psilocybin, or placebo. Estimated completion is April 2026, though topline results have not yet been reported as of May 2026. Usona's Phase 2 results, published in JAMA in August 2023, demonstrated a "rapid, large, and sustained antidepressant effect."

Helus Pharma (formerly Cybin, rebranded January 2026; Nasdaq: HELP) is developing CYB003/HLP003, a deuterated psilocin analog designed for reduced interpatient variability. The compound received FDA Breakthrough Therapy Designation for adjunctive MDD treatment. Phase 2 data showed a remarkable 75% remission rate after two doses at four months, with 71% remission and 100% response rates at 12 months. The Phase 3 PARADIGM program includes two trials: APPROACH (220 participants across 45 U.S. sites, data expected Q4 2026) and EMBRACE (330 participants, international sites).

GH Research develops GH001, an inhaled formulation of mebufotenin (5-MeO-DMT) for TRD. Its Phase 2b trial showed a striking -15.5 point placebo-adjusted MADRS reduction (p < 0.0001) and 57.5% remission at Day 8, with 73% remission at six months. The psychoactive experience lasts only about 11 minutes, requiring no psychotherapy. After the FDA lifted a clinical hold on January 5, 2026, GH Research plans to initiate its global pivotal Phase 3 program in 2026.

AtaiBeckley (the November 2025 merger of Atai Life Sciences and Beckley Psytech; Nasdaq: ATAI) is advancing BPL-003, an intranasal mebufotenin benzoate nasal spray for TRD that received Breakthrough Therapy Designation in October 2025. Phase 3 initiation is expected in Q2 2026.

Perhaps the most significant signal of mainstream pharma confidence came in August 2025 when AbbVie acquired Gilgamesh Pharmaceuticals for up to $1.2 billion, gaining bretisilocin (GM-2505), a novel psilocybin analog in Phase 2 for MDD. This marked the first major pharmaceutical company bet on psychedelic therapeutics at blockbuster-deal scale.

Definium Therapeutics (formerly MindMed, rebranded January 2026) does not have psilocybin programs but is advancing DT120, an LSD-derived compound with FDA Breakthrough Therapy Designation for generalized anxiety disorder, with three Phase 3 readouts expected in 2026. Filament Health supplies botanical psilocybin (PEX010) for over 50 clinical trials but has no Phase 3 program of its own. Enveric Biosciences remains in preclinical stages with its halogenated psilocybin derivative EB-003, targeting IND filing in 2026.

On February 23, 2026, the FDA granted Breakthrough Therapy Designation to Reunion Neuroscience's luvesilocin (RE104) for postpartum depression — a subcutaneous psilocybin-like compound that produced a 23-point MADRS reduction in Phase 2. A Phase 3 trial is planned for 2026.

---

Oregon's Pioneering Program Hits Growing Pains at 16,000 Clients

Oregon made history in November 2020 when voters passed Measure 109, creating the nation's first regulated psilocybin services program. After a two-year rulemaking period, licensed service centers began operating in the summer of 2023 under the Oregon Health Authority's Psilocybin Services (OPS) section.

The program has served approximately 16,000 clients and sold over 37,000 psilocybin products, generating more than $1.7 million in revenue. Roughly 60% of clients travel from out of state, since no Oregon residency requirement exists. Anyone 21 or older can access services without a prescription, medical referral, or diagnosis. The process involves contacting a licensed service center, completing a preparation session with a trained facilitator, and undergoing an administration session at the center — psilocybin cannot be taken home. Session costs range from $500 to $3,000+, though group sessions are more affordable, and average product prices have declined from approximately $85 in 2023 to an estimated $50 by mid-2026.

But the program faces sustainability challenges. Of the 35 service center licenses issued, roughly a third have closed — only about 23 remain operational as of early 2026, with further closures planned. High operating costs are the primary culprit: annual licensing fees of approximately $10,000, insurance rates triple the norm for health businesses (due to federal Schedule I status), and persistent banking difficulties. Additionally, 25 of Oregon's 36 counties have opted out of the program, severely limiting where centers can operate.

Oregon psilocybin service centers are concentrated in the Portland metro area and a handful of other cities. If you're looking for a licensed facilitator, Portland has the largest concentration of operational centers in the state.

Safety data has been encouraging: roughly two dozen reported adverse events out of 10,000+ clients, none resulting in hospitalization. The most common incident has been agitation or desire to leave the facility. Oregon established a 2026 Psilocybin Product Potency Workgroup and began publishing quarterly program data in Q1 2025. In a significant milestone, OHSU received a $3.3 million, five-year NIDA/NIH grant in February 2026 — the first-ever federal funding to study legal psilocybin services in community settings.

---

Colorado, New Mexico, and the Next Wave of State Programs

Colorado's Natural Medicine Health Act (Proposition 122), passed in November 2022, decriminalized personal possession, use, and cultivation of five natural psychedelic substances for adults 21+: psilocybin, psilocin, DMT, ibogaine, and mescaline (excluding peyote). The regulated healing center program initially covers only psilocybin and psilocin, though the Natural Medicine Advisory Board may recommend expanding to the other three substances after June 1, 2026.

The first licensed healing center — The Center Origin in Denver — opened in April 2025. As of February 2026, Colorado has 34 state-licensed healing centers approved, with more than a dozen applications pending. Two license types exist: standard healing centers and micro-healing centers (limited to less than 750 mg of psilocybin on-site, designed as add-ons for existing therapy practices). Session costs range from $1,500 to $3,400 depending on facility, and Colorado healing centers have opened in Denver, Boulder, Aspen, Golden, and Fort Collins, among other locations. Like Oregon, no residency requirement applies.

New Mexico broke new ground in April 2025 when Governor Michelle Lujan Grisham signed SB 219 (the Medical Psilocybin Act), making it the first state to legalize medical psilocybin through legislation rather than a ballot initiative. The law passed with overwhelming bipartisan support: 33-4 in the Senate and 56-8 in the House. Unlike Oregon and Colorado's wellness-oriented models, New Mexico adopted a medical model requiring administration by an approved, licensed healthcare provider in an approved clinical setting for qualifying conditions including treatment-resistant depression, PTSD, substance use disorders, and end-of-life care.

The law established a nine-member Medical Psilocybin Advisory Board (which held its first meeting on December 5, 2025) and appropriated $4.5 million for implementation, including a treatment equity fund for low-income patients and a research fund for state universities. While the statutory deadline for full implementation is December 31, 2027, the Department of Health announced an accelerated target to begin seeing initial patients by December 2026 — a full year ahead of schedule.

Texas has not legalized or decriminalized psilocybin but has emerged as a major psychedelic research hub. Governor Abbott signed SB 2308 in 2025, creating a $50 million public-private partnership — the largest state-funded psychedelic research initiative in U.S. history — focused on FDA-approved clinical trials for ibogaine in opioid use disorders. Separate legislation (HB 4014) would create a psilocybin research advisory council and clinical trial grants program, with a report due by December 1, 2026.

Several other states have made notable moves. New Jersey Governor Phil Murphy signed a $6 million psilocybin pilot program into law on January 21, 2026, creating hospital-based research at three facilities statewide. Minnesota's House Health Finance and Policy Committee approved a bipartisan psilocybin therapy bill on March 9, 2026, advancing it to the full chamber — one of the furthest any psilocybin bill has progressed in the Midwest. South Dakota's HB 1099 — a "trigger law" that would instantly legalize prescription psilocybin upon FDA approval and DEA rescheduling — passed the House 58-7 and cleared the Senate committee 6-0 in February 2026. Similar trigger laws have been introduced in Iowa, Kansas, Virginia, and West Virginia. Missouri, Iowa, New Hampshire, and Connecticut all have active psilocybin bills in various stages as of Q1 2026. Vermont, New York, and Minnesota also continue pursuing legislation. Washington state's broader legalization bills stalled for the fourth consecutive year, though a ballot initiative (Initiative 2076) is being drafted, and a University of Washington pilot program for veterans continues under 2023 legislation.

Over 20 U.S. cities and jurisdictions have decriminalized psilocybin or entheogenic plants, starting with Denver in May 2019 and including Oakland, Washington D.C., Seattle, Ann Arbor, Detroit, Cambridge, Somerville, Minneapolis, and others.

For a complete breakdown of every state's legal status, see our guide to psilocybin therapy legal states in 2026.

---

Trigger Laws: Why 90% of Americans Could Have Access Within 30 Days of Federal Approval

A quiet wave of state legislation in early 2026 has built a near-national framework that activates the moment FDA approves COMP360 and DEA reschedules the approved formulation. Compass Pathways disclosed on its May 13 earnings call that "almost 90% of the U.S. population live in a state that intends to reschedule COMP360 within 30 days after FDA approval and DEA rescheduling."

The mechanics matter: a trigger law instantly reclassifies an FDA-approved psilocybin formulation under state controlled-substances law upon federal action, eliminating the months-to-years lag that has historically existed between federal scheduling changes and state implementation.

Signed into law in 2026:

• South Dakota HB 1099 (signed March 24, 2026): Reclassifies FDA-approved crystalline polymorph psilocybin to Schedule IV under state law upon FDA approval.
• Virginia HB 1347 / SB 379 (signed April 13, 2026): Directs the Board of Pharmacy to reschedule FDA-approved psilocybin formulations administered in healthcare settings, consistent with federal scheduling.

In progress or stalled:

• Connecticut SB 191: Passed both chambers (Senate 35-0, House 122-27). Expands the state's psychedelic-assisted therapy pilot program and lowers age eligibility to 18. Awaiting Gov. Ned Lamont's signature as of May 25, 2026.
• Kansas HB 2218: In committee; carries over in two-year session.
• Iowa HF 978: Passed Senate Ways and Means Committee but did not come up for floor debate; died with session adjournment in early May 2026.

For patients in trigger-law states, the practical effect is that an FDA approval decision in Q4 2026 or Q1 2027 could translate to legal availability of prescribed COMP360 within weeks, not years, of the federal action — assuming insurance coverage, REMS-certified provider availability, and supply chain readiness all line up.

---

DEA Scheduling, Rescheduling Precedents, and What FDA Approval Would Change

Psilocybin remains a Schedule I controlled substance under the Controlled Substances Act, classified as having "no currently accepted medical use" — a designation in place since 1970. However, several developments signal potential movement.

The most significant is an active rescheduling petition. On August 11, 2025, the DEA formally transmitted a petition from Dr. Sunil Aggarwal and the Advanced Integrative Medical Science Institute to HHS/FDA, requesting evaluation of moving psilocybin from Schedule I to Schedule II. This followed a 2023 Ninth Circuit Court of Appeals ruling (Aggarwal v. U.S. DEA) directing the DEA to reconsider its prior denial. HHS is currently evaluating the petition, though no timeline for a response has been disclosed.

The DEA's own actions suggest recognition of psilocybin's growing legitimate use. In a final rule published January 5, 2026, the agency set 2026 aggregate production quotas for psilocybin at 50,000 grams (up from 30,000 in 2025) and for psilocin at 80,000 grams (up from 36,000) — more than doubling legal research production. The agency cited the quotas as necessary "to support manufacturing activities related to the increased level of research and clinical trials."

The marijuana rescheduling process offers both precedent and caution. The DEA proposed moving cannabis from Schedule I to Schedule III in May 2024 following an HHS recommendation, but the process remains stalled under the current administration. A notable April 2024 DOJ Office of Legal Counsel opinion clarified that a drug can have a "currently accepted medical use" without FDA NDA approval — a potentially significant precedent for psilocybin.

If FDA approves COMP360, the most likely outcome is formulation-specific rescheduling — only the approved product would be reclassified, while psilocybin as a substance remains Schedule I. This follows established precedent: GHB remains Schedule I while the FDA-approved formulation XYWAV is Schedule III; synthetic THC (Marinol) is Schedule III while other THC remains Schedule I. After FDA approval, HHS would recommend rescheduling to the DEA, which has 90 days to issue an interim final rule. The approved formulation would likely be placed in Schedule II or III.

This means Oregon and Colorado service centers using non-FDA-approved psilocybin would still technically operate with a Schedule I substance under federal law, even after COMP360's approval. Legal experts confirm that FDA-triggered rescheduling "will not affect" state service center markets, as those programs use state-regulated psilocybin rather than the FDA-approved formulation.

---

How FDA Approval Would Reshape Patient Access and Insurance Coverage

The distinction between FDA-approved psilocybin therapy and state-legalized access is fundamental to understanding who will benefit and when.

Under the Oregon and Colorado models, any adult 21 or older can access psilocybin at a licensed service center without a diagnosis, prescription, or medical referral. Facilitators need state-approved training but are not required to be medical professionals. The critical limitation is cost: sessions run $500–$3,400 out of pocket, with zero insurance coverage available because psilocybin remains a federally unscheduled substance with no FDA approval.

An FDA-approved prescription model would look very different. It would require a medical diagnosis (initially treatment-resistant depression), a physician's prescription, and administration in a certified clinical setting — likely with a REMS (Risk Evaluation and Mitigation Strategy) similar to esketamine (Spravato). The transformative advantage would be insurance reimbursement.

Spravato provides the closest precedent. Approved in March 2019 for TRD, it requires administration in REMS-certified facilities with two-hour post-administration monitoring. Major insurers including Cigna, Aetna, Blue Cross Blue Shield, UnitedHealthcare, Medicare (Part B), and Medicaid now cover it. Spravato generated $1.7 billion in sales in 2024, growing 57% year-over-year — demonstrating that supervised psychedelic-adjacent therapies can achieve blockbuster commercial success even with restrictive administration requirements.

The American Medical Association released three temporary CPT codes for psychedelic medication therapy monitoring in June 2023, laying groundwork for future billing infrastructure. An Emory University study estimates over 5 million Americans would be eligible for psilocybin-assisted therapy, with approximately 17 million Medicaid beneficiaries having clinical depression. COMPASS CEO Kabir Nath told Colorado Public Radio the company believes it can "get insurers or the government to pay for it."

The two models — state-regulated wellness access and FDA-approved medical treatment — will likely coexist, serving different populations with different needs. From a patient access standpoint, it means more pathways to treatment, not fewer. If you're looking to access psilocybin therapy today, browse our provider directory to find licensed centers in Oregon and Colorado.

---

Political Picture: From Contradiction to Clarity in Three Months

The political landscape for psilocybin shifted decisively between February and April 2026. In early February, STAT News reported that senior Trump administration officials had removed COMP360 from the FDA's Priority Voucher program just hours before its initial announcement — psilocybin was the only one of ten proposed drugs vetoed. This created an apparent contradiction with the administration's pro-psychedelic rhetoric from HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, and White House adviser Calley Means.

That contradiction resolved on April 18 with Executive Order 14401 and was confirmed operationally on April 24 when FDA issued CNPVs to Compass, Usona, and Transcend. Whatever the internal dynamics were in February, the administration's actual regulatory posture as of late spring 2026 is unambiguously supportive of accelerated psychedelic review for serious mental illness indications.

The FDA's August 2024 rejection of Lykos Therapeutics' MDMA application for PTSD — which saw the Psychopharmacologic Drugs Advisory Committee vote 9-2 against approval — continues to cast a shadow over the psychedelic space. However, experts largely view that rejection as reflecting trial-specific failures (selection bias, functional unblinding, ethical violations at one trial site) rather than opposition to psychedelics as a category. COMPASS Pathways intentionally designed its trials to address each of Lykos's deficiencies: using true placebo and low-dose active controls, enrolling psychedelic-naïve participants, collecting 26-week durability data, and positioning the psychological support component as distinct from standalone psychotherapy.

The FDA's June 2023 draft guidance document, "Psychedelic Drugs: Considerations for Clinical Investigations," remains in draft form as of May 2026 but provides the agency's clearest articulation of expectations for psychedelic clinical trial design, including standards for blinding, safety monitoring, psychological support, and discharge readiness. No Psychopharmacologic Drugs Advisory Committee meeting has been scheduled for psilocybin — such a meeting would likely occur after NDA filing, potentially in 2027.

A RAND survey released February 24, 2026 found that 23% of Americans support legal psilocybin use — a figure researchers noted mirrors cannabis support levels prior to the passage of the first medical cannabis laws. Among psilocybin users, 62% support legalization, and 49% of all respondents favor supervised medical facility use.

Meanwhile, federal research investment is accelerating. In November 2025, ARPA-H launched the $100 million EVIDENT initiative for rapid-acting behavioral health therapeutics including psychedelics. The OHSU grant and growing DEA production quotas add to evidence of deepening institutional commitment regardless of political headwinds.

---

Conclusion

The psilocybin landscape in 2026 has reached an inflection point where scientific evidence, regulatory frameworks, and political dynamics are converging — imperfectly but unmistakably — toward mainstream medical acceptance. COMPASS Pathways' two positive Phase 3 trials represent the strongest clinical dataset any classic psychedelic has ever produced, and its Q4 2026 NDA submission target puts an FDA approval decision within realistic reach by early 2027. The pipeline behind it is deep: at least four additional companies hold FDA Breakthrough Therapy Designations for psychedelic compounds, and AbbVie's $1.2 billion bet signals that Big Pharma sees this as a legitimate therapeutic category, not a fringe movement.

State-level access is no longer theoretical — roughly 16,000 people have received legal psilocybin in Oregon, Colorado's healing center network is rapidly expanding, and New Mexico's medical program could begin treating patients by year's end. The proliferation of trigger laws in states like South Dakota suggests that FDA approval would immediately unlock access far beyond the current pioneering states.

The most underappreciated development may not be the insurance question but the speed question. Six months ago, the consensus view in the field was that an FDA decision on COMP360 was unlikely before Q3 2027. With EO 14401, the April 24 CNPV grant, the rolling NDA submission already underway, and a trigger-law framework that already covers nearly 90% of the U.S. population, an FDA approval decision could realistically come in Q4 2026 or Q1 2027 — with state-level legal availability following within 30 days in most of the country. That telescoped timeline — from "years away" to "within a year, perhaps" — is the change that hasn't fully been absorbed by patients, providers, or payers. FDA approval, combined with DEA rescheduling of the approved formulation, would transform psilocybin from a $500–$3,400 out-of-pocket expense into a potentially covered treatment for millions of Americans with treatment-resistant depression. That shift — from wellness luxury to reimbursable medicine — is what separates a niche state program from a healthcare revolution. The science is now largely in. The regulatory and political machinery, for all its contradictions, has begun to grind forward faster than most observers expected.

---

Frequently Asked Questions

Is psilocybin FDA approved?

No. As of May 2026, psilocybin is not FDA approved for any indication. It remains a Schedule I controlled substance under federal law. COMPASS Pathways' COMP360 is the leading candidate for approval, having completed two successful Phase 3 trials for treatment-resistant depression, but the company has not yet submitted a New Drug Application (NDA) to the FDA.

When will psilocybin be FDA approved?

The earliest realistic FDA approval decision is Q4 2026 or Q1 2027, contingent on (1) Compass Pathways' rolling NDA submission completing in Q3 2026 after early Q3 Part B COMP006 data, and (2) FDA review under the Commissioner's National Priority Voucher program operating at its stated 1-2 month goal. Both FDA and Compass have characterized the 1-2 month review timeline as a program goal, not a binding statutory commitment. No PDUFA date has been set, as the NDA is not yet complete. The Eli Lilly Foundayo CNPV approval in 50 days (April 1, 2026) is a supportive precedent but a single data point.

Can I get psilocybin therapy now?

Yes — if you live in or can travel to Oregon or Colorado. Both states have operational, licensed psilocybin therapy programs open to any adult 21 or older, without a prescription or diagnosis. Oregon's psilocybin service centers have served over 16,000 clients since 2023. Colorado has 34 licensed healing centers open since 2025. Browse our provider directory to find a licensed center near you.

Will insurance cover psilocybin therapy?

Not yet. Insurance does not cover psilocybin therapy at Oregon or Colorado service centers because psilocybin remains federally unscheduled with no FDA approval. If COMP360 receives FDA approval and the DEA reschedules the approved formulation, insurance coverage could follow — following the precedent set by Spravato (esketamine), which is now covered by Medicare and major commercial insurers. Until then, all psilocybin therapy costs are paid out of pocket.

What is COMP360?

COMP360 is a synthetic, pharmaceutical-grade psilocybin formulation developed by COMPASS Pathways (Nasdaq: CMPS) for treatment-resistant depression. It received FDA Breakthrough Therapy Designation in 2018 and has now completed two successful Phase 3 clinical trials, making it the furthest-advanced psilocybin program in the world. A single 25 mg dose is administered in a supervised clinical setting with psychological support. COMPASS targets a rolling NDA submission in Q4 2026, with a potential FDA decision by late 2026 or early 2027.

---

---

Sources

• Psychedelic Alpha: After the Readout — How the Field Is Interpreting COMPASS Phase 3 Psilocybin Data (Sandeep Nayak quote)
• BioSpace: Psychedelics Space at a 'Tipping Point' as Compass, Definium Gear Up To File for Approval (Patrick Trucchio / H.C. Wainwright)
• Colorado Public Radio: Synthetic Psilocybin Nears FDA Review (Kabir Nath)
• Marijuana Moment: Trump Administration 'Very Anxious' To Allow Psychedelic Therapy, RFK Tells Joe Rogan
• Marijuana Moment: Exploring Psychedelic Medicine Is A 'Top Priority' For Trump Administration, FDA Commissioner Says
• STAT News: Psychedelics Proponents Hope Trump Administration Will Foster a New Era (Calley Means)

---

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making treatment decisions.